Mizuho Securities USA LLC Sells 2,818 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mizuho Securities USA LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 20.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,230 shares of the medical research company’s stock after selling 2,818 shares during the period. Mizuho Securities USA LLC’s holdings in IQVIA were worth $2,661,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IQV. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA during the 3rd quarter valued at about $147,683,000. 1832 Asset Management L.P. grew its position in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after acquiring an additional 376,595 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of IQVIA during the second quarter worth approximately $70,610,000. Impax Asset Management Group plc lifted its holdings in shares of IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Performance

IQVIA stock opened at $201.82 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The stock’s 50 day simple moving average is $222.67 and its two-hundred day simple moving average is $227.18. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.63 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.03 and a beta of 1.51.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.